Achiko Logo cropped.jpg
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20 avr. 2022 07h45 HE | Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Logo cropped.jpg
Achiko AG Research Paper and Commercialization Update
14 févr. 2022 07h30 HE | Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
Achiko Logo cropped.jpg
Achiko Announces the Successful Integration of its Teman Sehat Digital Ecosystem and AptameX Covid-19 Diagnostic Testing Platform for Launch in Indonesia
03 juin 2021 07h30 HE | Achiko AG
Wireless integration of AptameX Covid-19 test with Teman Sehat completedTeman Sehat’s open API allows for integration of third party testing platformsTeman Sehat provides results within 15 minutes,...
Achiko Logo cropped.jpg
Achiko Completes Initial Shipment of AptameX, its Progressive Covid-19 Diagnostic Test to Indonesia, Delivering 77% Sensitivity at Low Viral Loads
20 mai 2021 07h30 HE | Achiko AG
Production of First 1,000 AptameX Test Kits is Concluded in Singapore (initial capacity to test 10,000 patients per day).AptameX Delivers Sensitivity of 77% (95% CI: 75.94 - 79.24) at a High Industry...
Achiko Logo cropped.jpg
Achiko Appoints New Chief Financial Officer and Announces Changes to Senior Team
04 mai 2021 07h30 HE | Achiko AG
Appoints Robert Rieder as Chief Financial OfficerChief Operating Officer Chris Young to Retire Focus on Product Development, Lowering Cost Profile and Improved Alignment of Resources ZURICH,...
Achiko Logo cropped.jpg
Achiko Concludes Phase 1 Study of Project Gumnuts for Covid-19 Testing
25 janv. 2021 07h30 HE | Achiko AG
Completion of Phase 1 Testing Demonstrates 91% Sensitivity and 85% SpecificityFurther Optimization Studies are Currently Being Performed and are Expected to Continue to Improve Results and Match WHO...
Achiko Logo cropped.jpg
Achiko AG Enters into a Convertible Note of Up to CHF $2 Million with Negma Group
30 nov. 2020 08h30 HE | Achiko AG
ZURICH, Switzerland, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“the Company”) has entered into a new subordinated convertible loan transaction of up to CHF $2...
Achiko Logo cropped.jpg
Achiko Secures Convertible Loan Facility with Yorkville Advisors of USD $2.5 Million, with a Provisional Extension of Up to USD $9.5 Million
26 nov. 2020 07h00 HE | Achiko AG
ZURICH, Switzerland, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) announces the completion of a convertible loan facility with US based fund manager Yorkville Advisors...
Achiko Logo cropped.jpg
Achiko AG Appoints Toolbox Medical Innovations and NDA Group and Expands Advisory Board
02 nov. 2020 08h52 HE | Achiko AG
Encouraging Initial Results to Date in Field Validation TrialsToolbox Medical Innovations Engaged for the Design of the Commercial Test KitNDA Group Engaged to Assist in Progress Towards CE...
Achiko Logo cropped.jpg
Achiko Establishes MedTech Expert Advisory Board and Expands Management Team
13 oct. 2020 12h09 HE | Achiko AG
New international advisory board members: Mr. Glenn Cross (Australia), Dr. Jittaporn Wattanaseree (Thailand) and Ms. Carol Aebi (Switzerland)Management team appointment: Mr. Pierre Nathie of Med2Mark...